Apraglutide
Long-acting GLP-2 analog in Phase 3 for short bowel syndrome — a once-weekly successor to teduglutide's daily dosing burden.
Investigational compounds — read carefully
This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.
Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.
At a glance
Vectivbio (acquired by Ironwood Pharmaceuticals) is advancing apraglutide as a once-weekly GLP-2 receptor agonist for short bowel syndrome with intestinal failure — a substantial improvement on teduglutide's daily injection requirement.
- Class
- GLP-2 receptor agonist peptide
- Sponsor
- Ironwood Pharmaceuticals (via Vectivbio acquisition)
- Stage
- Phase 3
- Lead use case
- Short bowel syndrome with intestinal failure
What it is
Apraglutide is an engineered long-acting GLP-2 analog designed to provide once-weekly dosing for short bowel syndrome — addressing the principal practical limitation of the currently approved GLP-2 analog teduglutide (Gattex), which requires daily subcutaneous injection.
Current research status
Vectivbio (acquired by Ironwood Pharmaceuticals in 2023) advanced apraglutide through a Phase 3 STARS trial in adults with short bowel syndrome and intestinal failure. The trial reported positive topline results in 2024, supporting regulatory submissions in the U.S. and EU. If approved, apraglutide would represent a substantial dosing-frequency improvement over teduglutide.
Mechanistic rationale
Selective activation of the GLP-2 receptor in the intestinal mucosa, promoting epithelial proliferation, villus growth, and improved nutrient absorption. The mechanism is essentially the same as teduglutide; the differentiation is pharmacokinetic — engineered for once-weekly rather than daily dosing.
Available evidence
STARS Phase 3 trial (2024 readouts) — Apraglutide met the primary endpoint of reducing parenteral support volume in patients with short bowel syndrome and intestinal failure, supporting regulatory submission.[1]
Phase 2 trials — Established the once-weekly dosing rationale and supported translation into Phase 3.[2]
Why it's interesting
For the small but seriously-affected short-bowel-syndrome patient population, the daily-injection burden of teduglutide is a substantial quality-of-life issue. A once-weekly alternative with similar efficacy and safety would be a meaningful improvement. The orphan-disease economics also make this a relatively clean development pathway compared to the more crowded obesity space.
Limitations & risks
The patient population is small (orphan indication). The long-term safety profile of GLP-2 agonism — particularly the theoretical risk of GI tract neoplasia from sustained intestinal mucosal proliferation — remains a regulatory consideration as it has been throughout the teduglutide era. Phase 3 confirmation of safety alongside efficacy is the gating consideration.
Community discussion notes
Not a topic in fitness or biohacker communities. Significant interest in GI medicine and short-bowel-syndrome patient communities, where the daily-injection burden of teduglutide is a substantial practical issue.
The takeaway
Apraglutide is a clean example of pharmacokinetic engineering improving an existing drug class — taking GLP-2 agonism from daily to weekly dosing for a patient population where the dosing burden is meaningful. Phase 3 results support regulatory submission; if approved, it would become the practical successor to teduglutide for short bowel syndrome.
References
- Iyer K, et al. Apraglutide, a long-acting glucagon-like peptide-2 analog for short bowel syndrome with intestinal failure: STARS Phase 3 trial results. (2024.) https://pubmed.ncbi.nlm.nih.gov/?term=apraglutide+STARS
- Eliasson J, et al. Apraglutide, a novel once-weekly glucagon-like peptide-2 analog in short bowel syndrome. JPEN J Parenter Enteral Nutr. 2022;46(4):896-907. https://pubmed.ncbi.nlm.nih.gov/34738632/